Axillary vs sentinel lymph node dissectionfor invasive breast cancer [2]

JAMA

Volumn 305, Issue 22, 2011, Pages 2288-2289

  Chen, I Chun ^a   Lin, Ching Hung ^a   Lu, Yen Shen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AXILLARY LYMPH NODE EXTIRPATION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; HUMAN; INTERMETHOD COMPARISON; LETTER; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SENTINEL LYMPH NODE DISSECTION; SENTINEL LYMPH NODE METASTASIS; SURGICAL APPROACH; SURVIVAL; ADJUVANT CHEMOTHERAPY; AXILLA; BREAST TUMOR; DRUG ADMINISTRATION; FEMALE; LYMPHADENECTOMY; NOTE; REPRODUCIBILITY; SENTINEL LYMPH NODE BIOPSY; TIME; TREATMENT OUTCOME;

AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPH NODE EXCISION; REPRODUCIBILITY OF RESULTS; SENTINEL LYMPH NODE BIOPSY; TIME FACTORS; TREATMENT OUTCOME;

EID: 79958031307     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.751     Document Type: Letter

References (5)

1. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569-575.
2. Colleoni M, Bonetti M, Coates AS, et al; International Breast Cancer Study Group. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. J Clin Oncol. 2000;18(3):584-590. (Pubitemid 30078539)
3. Lohrisch C, Paltiel C, Gelmon K, et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2006;24(30):4888-4894. (Pubitemid 46630916)
4. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994;330(18):1253-1259.
5. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332(14):901-906.